Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer by Fankhauser, Christian Daniel et al.








Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients
with Cancer
Fankhauser, Christian Daniel ; Sweeney, Christopher J ; Connors, Jean M
DOI: https://doi.org/10.1016/j.eururo.2019.10.019





Fankhauser, Christian Daniel; Sweeney, Christopher J; Connors, Jean M (2020). Re: Rivaroxaban for
Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. European Urology, 77(3):388-390.
DOI: https://doi.org/10.1016/j.eururo.2019.10.019
Which genitourinary cancer patient should get 
prophylactic anticoagulation? 
Christian Daniel Fankhauser1, Christopher J Sweeney2 Jean M. Connors3 
1 Department of Urology, University of Zurich, Zurich, Switzerland 
2 Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA 
3 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 
 
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for Thromboprophylaxis in High-
Risk Ambulatory Patients with Cancer. New England Journal of Medicine. 2019 
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to Prevent Venous 
Thromboembolism in Patients with Cancer. The New England journal of medicine. 2019 
Experts’ summary 
Venous thromboembolic events (VTE) are common complications in patients with cancer 
[1]. In the CASSINI and AVERT trials ambulatory patients receiving systemic cancer 
therapy with an intermediate-to-high risk for VTE (Khorana score, ≥2) were randomized 
to either placebo or direct oral anticoagulants (DOACs) [2, 3]. The hazard ratios (HR) for 
VTE were reported as 0.66 and 0.41 together with HRs for bleeding of 1.96 and 2.00 
respectively. 
Experts’ comments 
The CASSINI and AVERT trials showed that prophylactic use of DOACs in cancer 
patients undergoing systemic therapy with an increased risk for VTE halves the risk of 
VTE and doubles the risk of bleeding [4, 5]. Previous findings for low molecular weight 
heparins (LMWH) found a similar relative risk reduction but a lower absolute risk reduction 
because of the less selective inclusion of patients. Ideally, our decisions would be based 
on randomized controlled trials powered to analyze the effect and risk of VTE in each 
genitourinary cancer individually, but unfortunately no such trial can be expected in the 
near future and physicians have to decide upon VTE prophylaxis on a daily base. In this 
report, we (1) underline the challenges to apply the current literature in genitourinary 
cancer patients, (2) provide a simple tool to decide which patient should get prophylactic 
anticoagulation and (3) draw attention to an important research niche. 
The main challenge is to identify patients at a sufficiently high risk for VTE to justify 
prophylactic anticoagulation, as there is an associated increased risk of bleeding. The 
CASSINI and AVERT trials used the Khorana risk model to determine a patient’s VTE 
risk. This model including five risk factors, was developed with 2701 patients but had a 
low rate of only 60 events. It was then validated in a cohort of 1365 patients that 
experienced even fewer events [6].  The model cohort included primarily 
adenocarcinoma, sarcoma and lymphoma patients, which each have distinct VTE 
etiologies – some of which are innate to the histology and others to local compression of 
venous system. Genitourinary cancers, including various histologies such as urothelial, 
clear cell, adenocarcinomas and germ cell tumors were not well represented in either the 
derivation or validation cohorts. Therefore, the Khorana risk model may not be adequate 
to determine the risk of VTE in genitourinary cancer patients and better genitourinary 
cancer specific risk scores are needed. How to determine the threshold for using VTE 
prophylaxis is currently unclear. 
The cut-off to initiate prophylaxis can be derived from CASSINI and AVERT trials as 
follows: The HR can be used to estimate the number needed to treat (NNT) with the 
following formula [7]: 
𝑁𝑁𝑁𝑁𝑁𝑁 = 1
(1 − cumulative incidence)HR– (1 − cumulative incidence) 
As shown in this formula, the NNT is not only influenced by the HR but also substantially 
driven by the cumulative VTE incidence. We plotted all estimated NNT for HRs between 
0.4-0.7 for a very low (1%) up to a very high (30%) cumulative VTE incidence in patients 
without prophylaxis. The NNT versus VTE risk curve illustrates that patients with a low 
risk of VTE do not benefit from prophylaxis. However, as the NNT decreases rapidly even 
with a more conservative HR of 0.7 for efficacy, the NNT falls below the number needed 
to harm (NNH) at a cumulative VTE incidence around 6%. In addition to calculating the 
NNT and NNH, other factors influence the use of anticoagulants in the prophylactic setting 
including ease of administration and financial cost to the patient. At a more general level, 
health economic modeling is needed to determine benefits to the society and this in turn 
is predicated by payer models.  This would also account for the cost of care for major 
pulmonary embolism requiring inpatient care, long term care of venous insufficiency and 
rare but lethal complications of bleeding and pulmonary embolism.  
This simple decision aid supports the treating clinician when trying to decide whether a 
patient should receive prophylactic anticoagulation or not. For example, prostate cancer 
patients during first- or second-line chemo- or hormonal therapy have a negligible 
cumulative VTE incidence and therefore the NNT would be unreasonably high in most 
cases. Another patient population at high risk for bleeding, such as patients with untreated 
primary in the urinary tract, would have a substantially lower NNH (red line in plot), 
changing the risk-benefit ratio.  We previously reported cumulative incidence VTE risks 
of over >8% in metastatic germ cell cancer patients [8], indicating that the NNT may be 
lower than the NNH and therefore prophylaxis could be justified. However, these 
cumulative VTE incident rates have to be confirmed in patients with or without other VTE 
risk factors. In summary, we acknowledge that the presented approach includes several 
strong assumptions, which need to be proven; therefore there is a need to develop 
genitourinary cancer specific VTE and bleeding risk scores to facilitate decision-making. 
In the meantime, this commentary can help clinicians taking care of patients with 
genitourinary malignancies decide on when to use prophylactic anti-coagulation. 
Figure legend 
Figure 1 NNT versus VTE risk curve Comparing the modeled number needed to treat 
according to cumulative risk of having a venous thrombo-embolic event against the 
number needed to harm. 
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